OBJECTIVE： This study aims to evaluate the bioactivity of five components of the traditional Chinese medicine complex prescription Jiangzhi granules against hepatocellular steatosis. METHODS： The five major componen...OBJECTIVE： This study aims to evaluate the bioactivity of five components of the traditional Chinese medicine complex prescription Jiangzhi granules against hepatocellular steatosis. METHODS： The five major components, including protopanaxadiol, tanshinone IIA, emodin, chlorogenic acid, and nuciferine, were extracted from Jiangzhi granules. Their cytotoxicity was assessed to determine the safe dose of each component for HepG2 cells. HepG2 cellular steatosis was induced using 1 mmol/L of free fatty acids （FFAs） for 24 h, and then treated with each component at high, intermediate, and low doses （500, 50, and 5 μmol/L）, respectively for another 24 h. The effects on HepG2 steatosis were observed directly under optical phase microscopy, or through oil red O staining and Nile red assays. In addition, the levels of reactive oxygen species （ROS） in the steatotic HepG2 cells with and without high-dose protopanaxadiol treatment were measured using fluorescent dye 2＇,7＇-dichlorodihydrofluorescein diacetate staining. RESULTS： No obvious cytotoxicity was observed in the HepG2 cells incubated with each of the five components at up to 500μmol/L. At 24 h after incubation with FFAs, the HepG2 cells swelled and many lipid droplets accumulated. The lipid content was attenuated after 24 h of incubation with protopanaxadiol, tanshinone IIA, and emodin at 500 or 50 μmol/L （P 〈 0.05）, especially with 500 μmol/L protopanaxadiol （P 〈 0.01）. In addition, the ROS level was elevated in steatotic cells, but decreased after intervention with 500μmol/L protopanaxadiol （P 〈 0.05）. CONCLUSION： Protopanaxadiol, tanshinone IIA, and emodin alleviate hepatocellular steatosis in a dose-dependent manner, and oxidative stress regulation may partially contribute to the effects of protopanaxadiol. ：展开更多
目的:观察降脂颗粒对非酒精性脂肪肝大鼠的治疗作用及其对血清瘦素、肝组织瘦素受体mRNA、P-JAK2/P-STAT3蛋白含量表达的影响.方法:将60只SD♂大鼠,随机分为空白组(正常饮食)和造模组(高脂饮食).待造模成功后将造模组大鼠随机分为模型...目的:观察降脂颗粒对非酒精性脂肪肝大鼠的治疗作用及其对血清瘦素、肝组织瘦素受体mRNA、P-JAK2/P-STAT3蛋白含量表达的影响.方法:将60只SD♂大鼠,随机分为空白组(正常饮食)和造模组(高脂饮食).待造模成功后将造模组大鼠随机分为模型对照组、降脂颗粒低、中、高剂量组和东宝甘泰组.治疗4 wk后行肝组织生化和病理学检测,并同时应用ELISA试剂盒检测血清瘦素,RT-PCR法检测肝组织瘦素受体mRNA表达,应用Western blot检测肝组织P-JAK2和P-STAT3蛋白的表达.结果:低、中、高剂量组降脂颗粒能明显降低非酒精性脂肪肝大鼠模型肝脂(TG和TC)水平,改善脂肪变性,降低肝脏炎症反应,并能明显降低血清瘦素高水平状态(193.02±23.8ng/ L,163.97±31.38ng/L,147.83±17.59ng/L vs 317.22±39.26ng/L,P<0.01),改善瘦素抵抗,同时增加瘦素受体mRNA的表达(1.87±0.06,2.20±0.04,2.78±0.04 vs 1.50±0.05,P<0.01),增加肝组织P-JAK2和P-STAT3蛋白的含量(119.88±2.98,123.45±0.68,124.34±3.42 vs 113.15±1.27,P<0.01;94.15±0.78,100.18±3.33,101.94±2.20 vs 89.06±0.69,P<0.01).结论:降脂颗粒对非酒精性脂肪肝大鼠肝脏脂质和炎症有较好的治疗作用,其可能机制是改善瘦素抵抗,增加肝脏瘦素受体mRNA表达及P-JAK2,P-STAT3蛋白含量.展开更多
基金supported by Natural Science Foundation of Shanghai (No. 11ZR1436900)Leading Academic Discipline Project, Shanghai Municipal Education Commission (No. J50305 & E03008)+1 种基金Innovation Program of Shanghai Municipal Education Commission(No. 12ZZ119)Budget Research Program of Shanghai Municipal Education Commission (No. 2010JW35)
文摘OBJECTIVE： This study aims to evaluate the bioactivity of five components of the traditional Chinese medicine complex prescription Jiangzhi granules against hepatocellular steatosis. METHODS： The five major components, including protopanaxadiol, tanshinone IIA, emodin, chlorogenic acid, and nuciferine, were extracted from Jiangzhi granules. Their cytotoxicity was assessed to determine the safe dose of each component for HepG2 cells. HepG2 cellular steatosis was induced using 1 mmol/L of free fatty acids （FFAs） for 24 h, and then treated with each component at high, intermediate, and low doses （500, 50, and 5 μmol/L）, respectively for another 24 h. The effects on HepG2 steatosis were observed directly under optical phase microscopy, or through oil red O staining and Nile red assays. In addition, the levels of reactive oxygen species （ROS） in the steatotic HepG2 cells with and without high-dose protopanaxadiol treatment were measured using fluorescent dye 2＇,7＇-dichlorodihydrofluorescein diacetate staining. RESULTS： No obvious cytotoxicity was observed in the HepG2 cells incubated with each of the five components at up to 500μmol/L. At 24 h after incubation with FFAs, the HepG2 cells swelled and many lipid droplets accumulated. The lipid content was attenuated after 24 h of incubation with protopanaxadiol, tanshinone IIA, and emodin at 500 or 50 μmol/L （P 〈 0.05）, especially with 500 μmol/L protopanaxadiol （P 〈 0.01）. In addition, the ROS level was elevated in steatotic cells, but decreased after intervention with 500μmol/L protopanaxadiol （P 〈 0.05）. CONCLUSION： Protopanaxadiol, tanshinone IIA, and emodin alleviate hepatocellular steatosis in a dose-dependent manner, and oxidative stress regulation may partially contribute to the effects of protopanaxadiol. ：
文摘目的:观察降脂颗粒对非酒精性脂肪肝大鼠的治疗作用及其对血清瘦素、肝组织瘦素受体mRNA、P-JAK2/P-STAT3蛋白含量表达的影响.方法:将60只SD♂大鼠,随机分为空白组(正常饮食)和造模组(高脂饮食).待造模成功后将造模组大鼠随机分为模型对照组、降脂颗粒低、中、高剂量组和东宝甘泰组.治疗4 wk后行肝组织生化和病理学检测,并同时应用ELISA试剂盒检测血清瘦素,RT-PCR法检测肝组织瘦素受体mRNA表达,应用Western blot检测肝组织P-JAK2和P-STAT3蛋白的表达.结果:低、中、高剂量组降脂颗粒能明显降低非酒精性脂肪肝大鼠模型肝脂(TG和TC)水平,改善脂肪变性,降低肝脏炎症反应,并能明显降低血清瘦素高水平状态(193.02±23.8ng/ L,163.97±31.38ng/L,147.83±17.59ng/L vs 317.22±39.26ng/L,P<0.01),改善瘦素抵抗,同时增加瘦素受体mRNA的表达(1.87±0.06,2.20±0.04,2.78±0.04 vs 1.50±0.05,P<0.01),增加肝组织P-JAK2和P-STAT3蛋白的含量(119.88±2.98,123.45±0.68,124.34±3.42 vs 113.15±1.27,P<0.01;94.15±0.78,100.18±3.33,101.94±2.20 vs 89.06±0.69,P<0.01).结论:降脂颗粒对非酒精性脂肪肝大鼠肝脏脂质和炎症有较好的治疗作用,其可能机制是改善瘦素抵抗,增加肝脏瘦素受体mRNA表达及P-JAK2,P-STAT3蛋白含量.
